IL167168A - Indoline compound in crystalline form for use in oral solid medicament and such oral solid medicament for treating dysuria - Google Patents

Indoline compound in crystalline form for use in oral solid medicament and such oral solid medicament for treating dysuria

Info

Publication number
IL167168A
IL167168A IL167168A IL16716805A IL167168A IL 167168 A IL167168 A IL 167168A IL 167168 A IL167168 A IL 167168A IL 16716805 A IL16716805 A IL 16716805A IL 167168 A IL167168 A IL 167168A
Authority
IL
Israel
Prior art keywords
oral solid
solid medicament
crystalline form
dysuria
indoline compound
Prior art date
Application number
IL167168A
Other languages
English (en)
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31973150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL167168(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of IL167168A publication Critical patent/IL167168A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
IL167168A 2002-09-06 2005-03-01 Indoline compound in crystalline form for use in oral solid medicament and such oral solid medicament for treating dysuria IL167168A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002262157 2002-09-06
PCT/JP2003/011345 WO2004022538A1 (ja) 2002-09-06 2003-09-05 経口用固形医薬用結晶およびそれを含む排尿障害治療用経口用固形医薬

Publications (1)

Publication Number Publication Date
IL167168A true IL167168A (en) 2010-11-30

Family

ID=31973150

Family Applications (1)

Application Number Title Priority Date Filing Date
IL167168A IL167168A (en) 2002-09-06 2005-03-01 Indoline compound in crystalline form for use in oral solid medicament and such oral solid medicament for treating dysuria

Country Status (23)

Country Link
US (1) US20060142374A1 (https=)
EP (1) EP1541554B1 (https=)
JP (1) JP4532274B2 (https=)
KR (1) KR100670592B1 (https=)
CN (1) CN1321111C (https=)
AT (1) ATE416159T1 (https=)
AU (1) AU2003264385B2 (https=)
BR (1) BR0314338A (https=)
CA (1) CA2496780C (https=)
DE (1) DE60325074D1 (https=)
ES (1) ES2316858T3 (https=)
HR (1) HRP20050214B1 (https=)
IL (1) IL167168A (https=)
IS (1) IS2640B (https=)
MX (1) MXPA05002549A (https=)
NO (2) NO329855B1 (https=)
NZ (1) NZ538598A (https=)
PL (1) PL375701A1 (https=)
RU (1) RU2347774C2 (https=)
TW (1) TW200407126A (https=)
UA (1) UA78854C2 (https=)
WO (1) WO2004022538A1 (https=)
ZA (1) ZA200501884B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1574215B1 (en) * 2002-12-16 2015-07-15 Kissei Pharmaceutical Co., Ltd. Solid drug for oral use
CA2557758C (en) 2004-03-05 2013-09-10 Kissei Pharmaceutical Co., Ltd. Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder
US20090227651A1 (en) * 2004-10-05 2009-09-10 Kissei Pharmaceutical Co., Ltd. Preventive and/or therapeutic agent for urine collection disorder accompanying lower urinary tract obstruction
PL1806136T3 (pl) * 2004-10-06 2012-04-30 Kissei Pharmaceutical Kompozycja medyczna do zapobiegania przejściu na leczenie operacyjne łagodnego rozrostu gruczołu krokowego
KR20070108388A (ko) * 2005-02-02 2007-11-09 테바 파마슈티컬 인더스트리즈 리미티드 가수소분해를 이용한 폴리펩타이드의 혼합물의 제조방법
PL1848415T3 (pl) * 2005-02-17 2013-10-31 Teva Pharma Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego
CN101557706B (zh) * 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
WO2008106125A2 (en) * 2007-02-26 2008-09-04 Concert Pharmaceuticals, Inc. Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
US20100076010A1 (en) * 2007-02-26 2010-03-25 Concert Pharmaceuticals, Inc. Alpha 1a-adrenoceptor antagonists
US20080242717A1 (en) * 2007-02-28 2008-10-02 Fumiyasu Sato Methods for treating benign prostatic hyperplasia
US8334409B2 (en) * 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
WO2012000926A1 (de) 2010-06-28 2012-01-05 Ratiopharm Gmbh Silodosin-cyclodextrin einschlussverbindungen
WO2012010669A2 (de) 2010-07-23 2012-01-26 Ratiopharm Gmbh Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer
WO2012014186A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Process for the preparation of silodosin and its novel intermediates
CN102229558B (zh) * 2010-08-05 2013-05-08 南京海纳医药科技有限公司 西洛多辛的晶型δ、它的制备方法和包含它的药物组合物
CN102229557B (zh) * 2010-08-05 2013-03-27 南京海纳医药科技有限公司 西洛多辛的半水合物晶体、制备方法和包含它的药物组合物
CN102010359B (zh) * 2010-09-10 2013-01-23 北京阳光诺和药物研究有限公司 β晶型西洛多辛的制备方法
WO2012077138A1 (en) * 2010-12-09 2012-06-14 Panacea Biotec Limited Methods of crystallizing (r) -1- (3 -hydroxypropyl) -5- [2- [2- [2- ( 2, 2, 2 - trifluoroethoxy) phenoxy] ethylamino] propyl] indoline-7 -carboxamide
EP2474529B1 (en) 2010-12-23 2014-05-14 Sandoz AG Crystalline forms of an active pharmaceutical ingredient
CN102283816B (zh) * 2011-08-05 2013-09-11 北京海步国际医药科技发展有限公司 西洛多辛缓释片剂及其制备方法
US20140243383A1 (en) * 2011-08-24 2014-08-28 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
WO2013072935A2 (en) 2011-10-10 2013-05-23 Cadila Healthcare Limited Process for the preparation of silodosin
WO2014157137A1 (ja) * 2013-03-26 2014-10-02 キッセイ薬品工業株式会社 シロドシンの苦味をマスキングした経口投与製剤
CN103159664B (zh) * 2013-03-29 2016-03-23 深圳市海滨制药有限公司 一种赛洛多辛原料药及其制备方法、药物组合物
WO2015015512A2 (en) * 2013-07-29 2015-02-05 Ind-Swift Laboratories Limited Process for the preparation of silodosin and its gamma form
JP2015117192A (ja) * 2013-12-17 2015-06-25 東和薬品株式会社 シロドシンγ型結晶及びその製造方法
US9643921B2 (en) 2014-02-06 2017-05-09 Ube Industries, Ltd. Method for producing indoline compound
KR20150127996A (ko) * 2014-05-08 2015-11-18 한미정밀화학주식회사 실로도신 감마형 결정의 제조방법
KR101725393B1 (ko) * 2014-07-24 2017-04-27 주식회사 경보제약 실로도신의 제조 방법 및 신규 중간체
KR101673160B1 (ko) 2014-10-24 2016-11-07 보령제약 주식회사 실로도신 γ 결정형의 제조방법
JP2016147811A (ja) * 2015-02-10 2016-08-18 ダイト株式会社 シロドシンγ型結晶の製造方法
ES2607639B1 (es) 2015-09-30 2018-02-28 Urquima, S.A Sal de ácido maleico de un intermedio de silodosina
KR101733084B1 (ko) 2016-07-27 2017-05-08 (주)다산메디켐 실로도신의 결정형의 제조방법
EP3354283B1 (en) 2017-06-20 2019-08-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical capsule composition comprising silodosin
JP2018035199A (ja) * 2017-12-07 2018-03-08 東和薬品株式会社 シロドシンγ型結晶及びその製造方法
CN107903201B (zh) * 2017-12-27 2020-09-25 浙江天宇药业股份有限公司 一种β晶型西洛多辛的制备方法
CN111410626B (zh) * 2019-01-04 2022-11-04 上海汇伦医药股份有限公司 赛洛多辛α-晶型的制备方法
CN109824569B (zh) * 2019-04-04 2022-09-20 重庆医药高等专科学校 一种西罗多辛晶型i及其制备方法
WO2020237643A1 (zh) * 2019-05-31 2020-12-03 上海汇伦生命科技有限公司 赛洛多辛α-晶型的制备方法
CN114601826B (zh) * 2022-03-31 2024-06-04 乐泰药业有限公司 一种用于治疗前列腺增生的药物制剂及其制备方法和质量检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69319551T2 (de) * 1992-12-02 1998-10-29 Kissei Pharmaceutical Indolin Verbindungen zur Behandlung von Dysurien
JP3331048B2 (ja) * 1994-06-01 2002-10-07 キッセイ薬品工業株式会社 インドール誘導体
AU9095998A (en) * 1997-09-22 1999-04-12 Kissei Pharmaceutical Co. Ltd. Remedies for dysuria resulting from prostatic hypertrophy
AU766088B2 (en) * 1998-02-27 2003-10-09 Kissei Pharmaceutical Co. Ltd. Indole derivatives and medicinal compositions containing the same
AU3011299A (en) * 1998-03-23 1999-10-18 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
JP4324266B2 (ja) * 1999-02-26 2009-09-02 キッセイ薬品工業株式会社 α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
JP4921646B2 (ja) * 2001-03-08 2012-04-25 キッセイ薬品工業株式会社 １−（３−ベンジルオキシプロピル）−５−（２−置換プロピル）インドリン誘導体およびその使用方法
CN101048376B (zh) * 2004-10-27 2011-03-23 橘生药品工业株式会社 二氢吲哚化合物及其生产方法

Also Published As

Publication number Publication date
RU2005109930A (ru) 2006-01-20
RU2347774C2 (ru) 2009-02-27
DE60325074D1 (de) 2009-01-15
KR20050057181A (ko) 2005-06-16
TWI305148B (https=) 2009-01-11
EP1541554A4 (en) 2006-11-08
PL375701A1 (en) 2005-12-12
NZ538598A (en) 2007-08-31
KR100670592B1 (ko) 2007-01-17
IS2640B (is) 2010-06-15
HRP20050214B1 (hr) 2013-09-30
CN1694867A (zh) 2005-11-09
NO20051709L (no) 2005-06-06
NO2011011I1 (no) 2011-07-25
CN1321111C (zh) 2007-06-13
TW200407126A (en) 2004-05-16
ZA200501884B (en) 2006-05-31
ES2316858T3 (es) 2009-04-16
JP4532274B2 (ja) 2010-08-25
UA78854C2 (en) 2007-04-25
JPWO2004022538A1 (ja) 2005-12-22
MXPA05002549A (es) 2005-06-03
AU2003264385B2 (en) 2009-12-17
BR0314338A (pt) 2005-07-05
WO2004022538A1 (ja) 2004-03-18
ATE416159T1 (de) 2008-12-15
NO329855B1 (no) 2011-01-10
AU2003264385A1 (en) 2004-03-29
NO2011011I2 (https=) 2012-10-01
US20060142374A1 (en) 2006-06-29
HRP20050214A2 (en) 2006-05-31
EP1541554B1 (en) 2008-12-03
CA2496780C (en) 2011-03-15
HK1084396A1 (en) 2006-07-28
IS7785A (is) 2005-04-05
CA2496780A1 (en) 2004-03-18
EP1541554A1 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
IL167168A (en) Indoline compound in crystalline form for use in oral solid medicament and such oral solid medicament for treating dysuria
IL148384A0 (en) Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
CA2476800A1 (en) Crystals of glucopyranosyloxybenzyl benzene derivative
MXPA04006003A (es) Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano.
EP1400529A4 (en) GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
GEP20064005B (en) Use of novel benzoimidazole derivatives as antiproliferative agents
GEP20043361B (en)  Crystalline Form of Perindopril Tert-Butylamine Salt,
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
WO2005044192A3 (en) Triazole compounds and uses related thereto
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
MY128014A (en) Thiol and thiocarbonyl derivatives which are useful as carboxypeptidase u inhibitors
RU2003118411A (ru) Кристаллические производные 1-метилкарбапенема
AP2004A (en) Polymorphic salt as an anti-migraine drug.
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
NO20044531L (no) Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom
SE0201837D0 (sv) Chemical compounds
SE9901572D0 (sv) New compounds
EP1179342A4 (en) IMMEDIATE RELEASE MEDICINAL COMPOSITIONS FOR ORAL ADMINISTRATION
NO20013601L (no) Nye morfolinobenzamidsalter
NO932382L (no) Heterocykliske forbindelser
SE0103272D0 (sv) Chemical compounds
EP1291349A4 (en) MALTO-OLIGOSACCHARIDE DERIVATIVES AND USE THEREOF
NO20045223L (no) Orto-substituerte benzosyrederivater for behandling av insulinresistens
IL143873A0 (en) Dry skin remedies

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed